Spero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary Disease and the SPR720 Program
03 October 2022 - 11:05PM
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset
clinical-stage biopharmaceutical company, focused on identifying,
developing and commercializing treatments in high unmet need areas
involving rare diseases and multi-drug resistant (MDR) bacterial
infections, today announced that it will host a virtual R&D
event on Thursday, October 6, 2022, at 11:30 a.m. Eastern Time.
The virtual event will feature a presentation by
key opinion leader, Kevin L. Winthrop, MD, MPH, from the Division
of Infectious Disease, OHSU Medical School. During his
presentation, Dr. Winthrop will discuss the etiology, unmet medical
need, and treatment landscape of non-tuberculous mycobacteria (NTM)
pulmonary disease. Members of the Spero management team will
provide an overview of the development program for SPR720, a
potential novel first line oral therapy for NTM infections.
A live Q&A session will follow the formal
presentations. To register for the event, please click here.
Dr. Winthrop Biography:
Kevin L. Winthrop, MD, MPH, Professor of Public
Health, Infectious Diseases, and Ophthalmology at Oregon Health and
Science University, is a former staff infectious disease
epidemiologist from the U.S. Centers for Disease Control and
Prevention’s Division of Tuberculosis Elimination. He has
co-authored over 300 publications, many detailing the epidemiologic
and clinical aspects of nontuberculous mycobacterial diseases,
tuberculosis, and other infections associated with rheumatic
diseases and biologic immunosuppressive therapies. Clinically, he
provides regional consultations for mycobacterial diseases and
other chronic chest infections and serves as the medical consultant
to the Oregon Public Health Division’s TB control program. His
Center for Infectious Disease Studies has served as the lead
institution and coordinating center for multiple cohort studies and
clinical trials. He has served as a primary or senior investigator
in many of these clinical and epidemiologic studies, and frequently
collaborates with the Pulmonary Department on studies related to
bronchiectasis. He founded the NTM Research Consortium and
associated Clinical Trials Network which facilitate collaborative,
multi-site grants and clinical trials among patients with NTM. He
is a member of the graduate faculty at OHSU where he mentors public
health students, medical students, and physicians in post-graduate
training.
About Spero TherapeuticsSpero
Therapeutics, headquartered in Cambridge, Massachusetts, is a
multi-asset, clinical-stage biopharmaceutical company focused on
identifying, developing, and commercializing novel treatments for
bacterial infections, including multi-drug resistant bacterial
infections and rare diseases.
- Spero Therapeutics is
developing SPR720 as a novel oral therapy candidate for the
treatment of a rare, orphan pulmonary disease caused by
non-tuberculous mycobacterial infections.
- Spero Therapeutics also has an
IV-administered next generation polymyxin product candidate,
SPR206, developed from its potentiator platform, which is in
development to treat multi-drug resistant Gram-negative infections
in the hospital setting.
- Tebipenem HBr is an investigational
drug in the United States being developed for the treatment of
cUTI, including pyelonephritis, caused by certain bacteria, in
adult patients who have limited treatment options; tebipenem HBr is
not FDA-approved.
For more information,
visit https://sperotherapeutics.com.
Forward Looking StatementsThis
press release may contain forward-looking statements. These
statements include, but are not limited to, statements about the
future development and commercialization of SPR720, SPR206, and
tebipenem HBr; and the design, initiation, timing, progress and
results of Spero's preclinical studies and clinical trials and its
research and development programs. In some cases, forward-looking
statements can be identified by terms such as “may,” “will,”
“should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intent,”
“target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “potential” or “continue” or the negative of these terms
or other similar expressions. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of various important factors, including whether tebipenem HBr will
advance through the clinical trial process on a timely basis, or at
all, taking into account the effects of possible regulatory delays,
slower than anticipated patient enrollment, manufacturing
challenges, clinical trial design and clinical outcomes; whether
the results of such trials will warrant submission for approval
from the FDA or equivalent foreign regulatory agencies; whether the
FDA will ultimately approve tebipenem HBr and, if so, the timing of
any such approval; whether the FDA will require any additional
clinical data or place labeling restrictions on the use of
tebipenem HBr that would delay approval and/or reduce the
commercial prospects of tebipenem HBr; whether a successful
commercial launch can be achieved and market acceptance of
tebipenem HBr can be established; the lengthy,
expensive, and uncertain process of clinical drug development for
SPR720 and SPR206; whether results obtained in preclinical studies
and clinical trials will be indicative of results obtained in
future clinical trials; Spero's reliance on third parties to
manufacture, develop, and commercialize its product candidates, if
approved; the ability to commercialize Spero's product candidates,
if approved; Spero's ability to retain key personnel; whether
Spero’s cash resources will be sufficient to fund its continuing
operations for the periods and/or trials anticipated; and other
factors discussed in the “Risk Factors” set forth in filings that
Spero periodically makes with the U.S. Securities and Exchange
Commission. The forward-looking statements included in this press
release represent Spero’s views as of the date of this press
release. Spero anticipates that subsequent events and developments
will cause its views to change. However, while Spero may elect to
update these forward-looking statements at some point in the
future, it specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Spero’s views as of any date subsequent to the date of
this press release.
Investor Relations Contact: Ted
JenkinsVice President, Investor Relations and Strategic
FinanceIR@sperotherapeutics.com (617) 798-4039
Media Inquiries:Matt Dick, Health Media
RelationsZeno Groupmatt.dick@zenogroup.com301-509-8532
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Apr 2024 to May 2024
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From May 2023 to May 2024